Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0169 • ACR Convergence 2024
Impact of Sense of Control Among People Living with SLE
Amanda Eudy¹, S. Sam Lim², Charmayne M. Dunlop-Thomas³, Jinoos Yazdany⁴, Patti Katz⁵ and Laura Plantinga⁶, ¹Duke University, Raleigh, NC, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: SLE is a disease characterized by cycles of remitting and relapsing symptoms that can be unpredictable, stressful, and cause an individual to feel they…
Abstract Number: 0194 • ACR Convergence 2024
Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus
Ariana Gonzalez-Melendez¹, Jeann Hernandez-Franco², Dylan Cedres-Rivera³ and Abiel Roche-Lima³, ¹University of Puerto Rico - Medical Science Campus, Guaynabo, PR, ²University of Puerto Rico, San Juan, PR, Puerto Rico, ³Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, San Juan, PR, Puerto Rico
Background/Purpose: The most common cause of death among patients with systemic lupus erythematosus (SLE) is cardiovascular disease (CVD). Previous studies have performed cardiovascular risk stratification;…
Abstract Number: 0362 • ACR Convergence 2024
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
Anna Deck¹, Paula Caras², Kiran Singh³, Monique Gore-Massy⁴, Faye Chiu⁵, Sara Folta⁶ and Shanthini Kasturi³, ¹Tufts University School of Medicine, Portland, ME, ²Tufts University School of Medicine, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Lupus Foundation of America, New Jersey, ⁵N/A, New York City, NY, ⁶Tufts University/Tufts University Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
Abstract Number: 0448 • ACR Convergence 2024
A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities
Divya Singh¹, Maya Faison², Molly Leavitt³, Megan Clowse⁴ and Cuoghi Edens⁵, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chapel Hill, NC, ³MacNeal Hospital/Loyola Medicine, Chicago, IL, ⁴Duke University, Chapel Hill, NC, ⁵Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: Nearly half of systemic lupus erythematosus (SLE) patients will experience pregnancy complications. These complications include increased rates of prematurity, miscarriage, pre-eclampsia, and mortality. Maternal…
Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 0676 • ACR Convergence 2024
Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research
Jeanette Andersen¹, Ina Meyer², Neeta Camadoo³, Tracy Machado⁴, Shreya Saraf⁴ and Mohamed Akrout², ¹Lupus Europe, Brussels, Belgium, ²F. Hoffmann-La Roche Ltd, Basel, ³Roche Products Ltd, Welwyn Garden City, ⁴Elma Research International, London
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that affects multiple organs, including the skin, joints, lungs, heart, kidneys and brain.…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1059 • ACR Convergence 2024
The Negative Impact of Physicians’ Neuroticism and Conscientiousness on Shared Decision Making in Patients with Systemic Lupus Erythematosus: The TRUMP2-SLE Project
Shigemi Morishita¹, Kenei Sada², Masataka Kudo³, Naofumi Dobashi⁴, Ryusuke Yoshimi⁵, Natsuki Sakurai⁶, Chiharu Hidekawa⁶, Yasuhiro Shimojima⁷, Dai Kishida⁷, Takanori Ichikawa⁷, Yoshi Miyawaki⁸, Keigo Hayashi⁹, Kenta Shidahara¹⁰, Yuichi Ishikawa¹¹, Nao Oguro¹², Nobuyuki Yajima¹³ and Noriaki Kurita¹⁴, ¹Department of Surgery, Oida Hospital, Sukumo, Japan, ²Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ³Department of General Internal Medicine, Iizuka Hospital, Fukuoka, Japan, ⁴Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital, Sukumo, Japan, ⁵Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Yokohama, Kanagawa, Japan, ⁶Department of Stem Cell and Immune Regulation,Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ⁷Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ⁸Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁹Brigham and Women’s Hospital, Brookline, MA, ¹⁰"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ¹¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ¹³Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁴Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan
Background/Purpose: The treatment of systemic lupus erythematosus (SLE) remains challenging due to its complexity, despite the introduction of various promising treatments. Recent EULAR recommendations emphasize…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
Abstract Number: 1485 • ACR Convergence 2024
Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
Rashmi Dhital¹, Jia Yin Wan², Kenneth Kalunian³ and Wendy Cozen⁴, ¹UC San Diego, Brentwood, TN, ²Samueli School of Public Health, University of California Irvine, Irvine, CA, ³University of California San Diego, La Jolla, CA, ⁴University of California Irvine, Irvine
Background/Purpose: Systemic lupus erythematosus (SLE) is influenced by both genetic and environmental factors. Twin studies in SLE have shown varying levels of concordance. This study…
Abstract Number: 1502 • ACR Convergence 2024
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. The aim of this study is to evaluate…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 1535 • ACR Convergence 2024
Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé², Ami Grunbaum³, Sasha Bernatsky⁴ and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tacrolimus is a pregnancy-compatible immunosuppressive increasingly used in systemic lupus erythematosus (SLE) pregnancies. Physiological changes throughout pregnancy impact tacrolimus pharmacokinetics, altering the drug’s whole…

« Previous Page
1
…
5
6
7
8
9
…
150
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].